Placebo for MK-7262

Phase 2

Merck & Co.

Placebo for MK-7262 is one of 3 therapeutic programs targeting Lipoprotein(a). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lipoprotein(a)Recruiting

Lipoprotein(a)Phase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Lipoprotein(a)

#DrugCompanyPhaseTrials

Enlicitide

Merck & Co.

Phase 2

1 2

Mk-7262

Merck & Co.

Phase 2

1 3

Placebo for MK-7262

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Lipoprotein(a)

NCT07614984

Clinical

Trials by Indication[1]

Lipoprotein(a)1 trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and When Coadministered With Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07614984·750 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo for MK-7262. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo for MK-7262. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Merck & Co.

Placebo for MK-7262

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lipoprotein(a)1 trial

References

Drug Info

Quick Facts

Related News